Aurobindo gets nod from USFDA for insomnia capsule

New Delhi, Jun 10 (UNI) Drugmaker Aurobindo Pharma Ltd today said said it has received final approval from the US Food and Drug Administration to manufacture and market zaleplon capsules of 5mg and 10mg.

The Hyderabad-based firm said in a statement that the drug is the generic equivalent of King Pharmaceuticals Inc's Sonata, used to treat insomnia, a statement said.

This is Aurobindo's 70th ANDA approval from the USFDA.

Aurobindo is in the first line of generics and got the USFDA nod on the very first day post the expiry of the relevant patent and has already launched the products in the US market.

UNI SBA MP KN1507